Multiple Myeloma

CCO&rsquo s expert faculty review and share their expert perspectives on key findings in multiple myeloma presented at the 2019 ASH annual meeting.

Share

Program Content

Activities

  • ASH 2019: Myeloma
    My Thoughts on Key Studies in Myeloma From ASH 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2020

    Expires: February 24, 2021

Activities

STOMP: Selinexor + Pd
Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

CC-93269 in MM
First Clinical Study of CC-93269, a BCMA 2+1 T-Cell Engager, in Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Phase Ib/II CARTITUDE-1
Phase Ib/II CARTITUDE-1 Study of BCMA-Directed CAR T-Cell Therapy JNJ-4528 in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

LEGEND-2: LCAR-B38M in R/R MM
LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

CASSIOPET: PET/CT in MM
CASSIOPET: CASSIOPEIA Companion Study Evaluating Prognostic Value of PET/CT in Newly Diagnosed, Transplant-Eligible Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

HOVON 143: IxaDaraDex in ND MM
Phase II HOVON 143 Trial: Interim Analysis of Ixazomib/Daratumumab/Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

GEM-CESAR: KRd in SMM
Phase II GEM-CESAR: Carfilzomib/Lenalidomide/Dexamethasone as Curative Regimen for High-Risk Smoldering Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

ALCYONE 3-Yr Follow-Up
ALCYONE 3-Yr Follow-up: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

MASTER: Dara-KRd in NDMM
MASTER Trial: Response-Adapted Dara-KRd Sequential Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Daratumumab + IRd With Dose-Modified Dex in NDMM
Phase II Trial of Daratumumab Plus Ixazomib/Lenalidomide/Dose-Modified Dexamethasone in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

Venetoclax + Dex in R/R MM
Phase I/II Study of Venetoclax + Dexamethasone in Patients With t(11;14) R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

CANDOR: KdD in R/R MM
Phase III CANDOR Trial of Carfilzomib, Dexamethasone ± Daratumumab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Venetoclax/Dara/Dex ± Bortezomib in R/R MM
Venetoclax/Daratumumab/Dexamethasone ± Bortezomib in Patients With R/R MM: Initial Analysis of a Phase I/II Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
GRIFFIN: VRd ± Dara
GRIFFIN Update: Phase II Study of Daratumumab + VRd vs VRd Alone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
GEM-CLARIDEX: Rd ± Clarithromycin
Phase III GEM-CLARIDEX: Clarithromycin Plus Rd vs Rd Alone in Newly Diagnosed, Transplant-Ineligible Patients with Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company